More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$10.88B
EPS
13.51
P/E ratio
14.7
Price to sales
0.82
Dividend yield
--
Beta
0.871192
Previous close
$174.22
Today's open
$174
Day's range
$172.78 - $176.69
52 week range
$101 - $247.49
show more
CEO
Javier J. Rodriguez
Employees
78000
Headquarters
Denver, CO
Exchange
New York Stock Exchange
Shares outstanding
62900000
Issue type
Common Stock
Healthcare
Healthcare Providers & Services
DaVita Expands Availability of Advanced Dialysis Therapy to Every U.S. Center
Expanded HD removes a broader range of toxins from the blood, with 95% of patients adopting the therapy within two weeks of nationwide rollout DENVER, Nov. 17, 2026 /PRNewswire/ -- DaVita today announced a major milestone in kidney care: Expanded hemodialysis (Expanded HD) is now available at every DaVita center in the U.S., giving patients nationwide access to an advanced therapy that removes more of the larger toxins, known as middle molecules, that conventional high-flux hemodialysis leaves behind. Within two weeks of the nationwide rollout, physicians have prescribed Expanded HD for 95% of eligible patients, reflecting rapid adoption across communities with different geographies, demographics and resource levels.
PRNewsWire • Nov 17, 2026

DaVita Expects Fewer Dialysis Treatments in Q4, but Higher Revenue per Visit Could Help Offset the Drop
DaVita NYSE: DVA expects a meaningful sequential decline in dialysis treatments in the fourth quarter because of calendar effects, but higher revenue per treatment should help offset the impact, Chief Financial Officer Joel Ackerman said at the Wolfe Healthcare Conference.
MarketBeat • Nov 13, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DaVita Inc. ("DaVita" or the "Company") (NYSE: DVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PRNewsWire • Nov 12, 2026

DVA Investors Have Opportunity to Join DaVita Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $DVA--DVA Investors Have Opportunity to Join DaVita Inc. Fraud Investigation with SBS Law.
Business Wire • Nov 12, 2026

Dialysis Giants DaVita and Fresenius Blocking Competition In Washington, Lawsuit Accuses
Washington Attorney General Nick Brown on Tuesday filed a lawsuit accusing the state's two largest for-profit dialysis providers of imposing illegal noncompete agreements on medical directors, blocking competition and reducing care options for kidney failure patients.
Benzinga • Nov 12, 2026

DaVita HealthCare (DVA) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research • Nov 11, 2026

DaVita Sees Growth and Drug Savings Offsetting 2027 Reimbursement Pressure
DaVita NYSE: DVA expects stronger dialysis treatment growth and pharmaceutical cost savings to help offset reimbursement pressures in 2027, though Chief Financial Officer Joel Ackerman said changes in patients' insurance coverage will remain a significant headwind.
MarketBeat • Nov 10, 2026

DaVita Inc. (DVA) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
DaVita Inc. (DVA) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
Seeking Alpha • Nov 10, 2026

DaVita Inc. (DVA) Presents at 2026 UBS Global Healthcare Conference Transcript
DaVita Inc. (DVA) Presents at 2026 UBS Global Healthcare Conference Transcript
Seeking Alpha • Nov 9, 2026

Lowey Dannenberg, P.C. is Investigating DaVita Inc. (NYSE: DVA) for Potential Violations of the Federal Securities Laws
NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating DaVita Inc. (NYSE: DVA) (“DaVita” or the “Company”) for potential violations of the federal securities laws.
GlobeNewsWire • Nov 9, 2026

¹ Disclosures

Open an M1 investment account to buy and sell DaVita Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.